Venture Kick

Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.

Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Translation-X is a spin-off project that develops novel therapeutics for Autism spectrum disorders.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

The most comprehensive blood test, via multi-omics and AI, for disease risk identification and prevention planning.

Pace Locator's aim is to leverage the potential of common, noninvasive patient data to enable faster, more reliable diagnosis and, eventually, safer, more successful treatment.

HeroSupport is a medical device manufacturing company that transforms imaging and/or treatment tables into personalized solutions. The company was founded in 2019 and is headquartered in Veyrier, Geneva.

AlpineWell developing novel solutions to hunger and swallowing difficulties, AlpineWell produces patient-centric food for special medicinal purposes (FSMP) and also provides automatic nutrition tracking to detect malnutrition early on.

Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye examinations through collaborations with opticians, retirement homes, and various companies. The company's services include remote assessments conducted by board-certified ophthalmologists, utilizing a secure cloud platform and advanced medical artificial intelligence to enhance the screening process. This approach aims to enable opticians and pharmacies to effectively detect blindness and prevent vision loss, ensuring that individuals receive timely and accurate eye care.

Our metabolic fingerprint is an end-to-end metabolic health solution for healthcare providers to assess individuals' metabolic health with minimum invasiveness and competitive cost. We use saliva as the bio-fluid for metabolite measurements analyzed with highly sensitive Nuclear Magnetic Resonance (NMR) spectrometers, running our custom analytical methods. Delivered to healthcare professionals on an easy-to-use, intuitive data platform for healthcare professionals.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.

NALU offers personalized digital therapies for menstrual disorders. Their side-effect-free alternative to hormone-based therapies addresses issues like menstrual pain, endometriosis, and missing periods.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

YLAH specializes in creating web and mobile applications tailored for psychotherapists and their patients. The company focuses on developing technology that delivers individualized therapies, clinical assessments, and health monitoring. This digital tool enables therapists to enhance and scale their services effectively, improving the overall therapeutic experience for patients.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Resmonics, established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen, specializes in privacy-friendly acoustic artificial intelligence designed to analyze soundscapes in various environments. Its primary focus is on detecting symptoms of infectious lung diseases, particularly for chronic disease management and monitoring respiratory symptoms. The company's flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics to foster healthy and productive working conditions. Additionally, Resmonics develops tools that provide objective, clinically validated insights into respiratory health, offering early warnings for potential crises and enhancing patient care through mobile applications.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.

Helvitek Labs, founded in 2019 and based in Lausanne, specializes in developing advanced anti-pollution face masks. The company was established by Théo-Tim Denisart, a graduate of the Swiss Federal Institute of Technology in Lausanne, and Roberto Costa, a former marketing director at Swatch, motivated by their experiences with severe air pollution in China. Helvitek Labs focuses on integrating artificial intelligence with innovative filtering and sealing technologies to improve mask comfort and effectiveness, particularly for health professionals who endure prolonged use of traditional respirators. Their efforts have garnered significant support, including recognition at the Start Lausanne contest and grants from the EPFL and the Vaud Foundation for Technological Innovation, which enabled the firm to establish itself within the EPFL Innovation Park and build a dedicated team. Officially incorporated as a public limited company in March 2020, Helvitek Labs aims to address the challenges associated with air quality and mask usage.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.

SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.

EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.

Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

Hi-D Imaging AG, founded in 2019 and based in Winterthur, Switzerland, specializes in a SaaS-based pre-operational planning platform tailored for cardiac procedures, particularly trans-catheter aortic valve implantation. The platform assesses the hemodynamics of patient-specific anatomies, allowing physicians to analyze blood flow patterns and perform in-vitro fluid dynamic analyses. This technology enables the selection of the optimal size and shape of heart valves, facilitating personalized solutions for patients with aortic stenosis before cardiac surgery. By streamlining pre-operational planning and enhancing data-driven decision-making, Hi-D Imaging aims to improve outcomes for patients with cardiovascular diseases while reducing the need for unnecessary medical imaging examinations. The company's AI-based cardiac image processing technology further supports medical professionals by producing detailed images of cardiac structures, thereby decreasing planning times and addressing the limitations of traditional medical scans.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.

CorasMedical is the development, production and sale of medical devices. It may set up branches and agencies at home and abroad, set up subsidiaries, participate in other ventures, acquire, manage and dispose of intellectual property and real estate, and enter into all business and contracts that directly or indirectly promote the purpose of the Company or which concern the investment and management of the Company's assets.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.

Rapid Graft develops a novel dermatome to easily take small split-skin grafts to improve treatment of chronic wound patients and to cover future needs in tissue engineering. Rapid Graft is headquartered in Zurich, Switzerland.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

NeaSens help protect people from radon, a natural gas and cause of lung cancer.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

SNAQ GmbH, based in Zurich, Switzerland, offers a mobile application that utilizes machine learning and computer vision technology to recognize food items and calculate portion sizes from images. By linking this information with a comprehensive nutrition database, the application provides users with detailed nutritional information, including carbohydrate, calorie, and protein content of their meals. SNAQ's innovative solution has been showcased at various diabetes conferences across Europe, emphasizing its relevance in the medical field and its potential to support health and lifestyle management.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietary technology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

Flares Analytics provides a device which is able to detect early signs of the COPD.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Comphya is focused on developing an innovative implantable medical device aimed at restoring erectile function in patients who do not respond to oral medications for erectile dysfunction (ED). The company's device utilizes self-controlled stimulation through a wireless remote control that targets the cavernous nerve, thereby enabling patients to regain natural erectile function. This approach offers a safe and effective alternative for a significant segment of the male population experiencing ED, ultimately enhancing their quality of life.

Liberty MedTech will solve a vital problem to all person affected with mobility problem with a simple revolutionary solution.

Aesyra SA, founded in 2017 and based in Lausanne, Switzerland, specializes in the design and manufacture of medical devices focused on managing sleep disorders. The company's flagship product, AesyBite, is an intra-oral sensor that monitors and alleviates sleep bruxism, a condition characterized by teeth grinding during sleep. Aesyra's technology enables dental professionals to conduct intraoral measurements while patients sleep, allowing for the detection of bruxism and other sleep-related issues, such as obstructive sleep apnea. By providing accurate monitoring and biofeedback alternatives, Aesyra aims to help healthcare providers reduce damage to dental prostheses caused by occlusal problems and improve overall sleep quality for their patients.